Literature DB >> 11096771

Systemic and Central Nervous System Vasculitides.

.   

Abstract

The vasculitides are a collection of diseases sharing the central feature of tissue injury due to inflammation of blood vessels. Although some occur frequently, many are encountered uncommonly or rarely. Nonetheless, because peripheral or central nervous system abnormalities may be a prominent part of these disorders, neurologists should know or be able to refer to studies on the classification, pathophysiology, treatments, and long-term complications of vasculitis. Two central issues that confront us now are 1) improving the accuracy of diagnosis, including identifying any underlying infectious causes, and 2) limiting the long-term damage from both the disease and its therapies.

Entities:  

Year:  2000        PMID: 11096771     DOI: 10.1007/s11940-000-0044-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  71 in total

1.  Inhibition of vascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of beta-interferon.

Authors:  D Stephan; H San; Z Y Yang; D Gordon; S Goelz; G J Nabel; E G Nabel
Journal:  Mol Med       Date:  1997-09       Impact factor: 6.354

Review 2.  Mood and cognitive side effects of interferon-alpha therapy.

Authors:  A D Valentine; C A Meyers; M A Kling; E Richelson; P Hauser
Journal:  Semin Oncol       Date:  1998-02       Impact factor: 4.929

3.  A controlled trial of azathioprine in Behçet's syndrome.

Authors:  H Yazici; H Pazarli; C G Barnes; Y Tüzün; Y Ozyazgan; A Silman; S Serdaroğlu; V Oğuz; S Yurdakul; G E Lovatt
Journal:  N Engl J Med       Date:  1990-02-01       Impact factor: 91.245

4.  Reduced gonadal toxicity after i.v. cyclophosphamide administration in patients with nonmalignant diseases.

Authors:  M Haubitz; C Ehlerding; K Kamino; K M Koch; R Brunkhorst
Journal:  Clin Nephrol       Date:  1998-01       Impact factor: 0.975

5.  Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.

Authors:  V Hamuryudan; C Mat; S Saip; Y Ozyazgan; A Siva; S Yurdakul; K Zwingenberger; H Yazici
Journal:  Ann Intern Med       Date:  1998-03-15       Impact factor: 25.391

Review 6.  Evaluation, treatment, and prophylaxis of infections complicating systemic vasculitis.

Authors:  M C Sneller
Journal:  Curr Opin Rheumatol       Date:  1998-01       Impact factor: 5.006

7.  Disease pattern in cranial and large-vessel giant cell arteritis.

Authors:  A Brack; V Martinez-Taboada; A Stanson; J J Goronzy; C M Weyand
Journal:  Arthritis Rheum       Date:  1999-02

8.  Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients.

Authors:  L Guillevin; P Cohen; M Gayraud; F Lhote; B Jarrousse; P Casassus
Journal:  Medicine (Baltimore)       Date:  1999-01       Impact factor: 1.889

9.  Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease.

Authors:  S Hirohata; H Suda; T Hashimoto
Journal:  J Neurol Sci       Date:  1998-08-14       Impact factor: 3.181

10.  Outcome of polyarteritis nodosa and Churg-Strauss syndrome. An analysis of twenty-five patients.

Authors:  M Abu-Shakra; H Smythe; J Lewtas; E Badley; D Weber; E Keystone
Journal:  Arthritis Rheum       Date:  1994-12
View more
  2 in total

Review 1.  Central nervous system vasculitis.

Authors:  Sterling G West
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

2.  Central nervous system vasculitis: still more questions than answers.

Authors:  Marco A Alba; Georgina Espígol-Frigolé; Sergio Prieto-González; Itziar Tavera-Bahillo; Ana García-Martínez; Montserrat Butjosa; José Hernández-Rodríguez; Maria C Cid
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.